Business Description
Abeona Therapeutics Inc
NAICS : 325413
SIC : 2834
ISIN : US00289Y2063
Total Employee Number:
226Compare
Compare
Traded in other countries / regions
ABEO.USA0H7R.UKPCJ.Germany Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
1980-09-19Description
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.39 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | -0.28 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -2.4 | |||||
Beneish M-Score | 54.3 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -21.2 | |||||
3-Year FCF Growth Rate | 38.7 | |||||
3-Year Book Growth Rate | 24.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 209.53 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.45 | |||||
9-Day RSI | 35.63 | |||||
14-Day RSI | 40.62 | |||||
3-1 Month Momentum % | 21.8 | |||||
6-1 Month Momentum % | 23.19 | |||||
12-1 Month Momentum % | -7.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.63 | |||||
Quick Ratio | 6.4 | |||||
Cash Ratio | 5.92 | |||||
Days Inventory | 178.99 | |||||
Days Sales Outstanding | 103.65 | |||||
Days Payable | 201.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -45.9 | |||||
Shareholder Yield % | 0.15 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.04 | |||||
Operating Margin % | -327.65 | |||||
Net Margin % | -246.42 | |||||
EBITDA Margin % | -279.4 | |||||
FCF Margin % | -319.46 | |||||
OCF Margin % | -299.53 | |||||
ROE % | -40.99 | |||||
ROA % | -29.25 | |||||
ROIC % | -220.97 | |||||
3-Year ROIIC % | -248.92 | |||||
ROC (Joel Greenblatt) % | -481.99 | |||||
ROCE % | -40.19 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 87.65 | |||||
PS Ratio | 13.77 | |||||
PB Ratio | 2.67 | |||||
Price-to-Tangible-Book | 2.67 | |||||
EV-to-EBIT | -2.86 | |||||
EV-to-EBITDA | -3.01 | |||||
EV-to-Revenue | 8.41 | |||||
EV-to-Forward-Revenue | 4.01 | |||||
EV-to-FCF | -2.63 | |||||
| Price-to-Net-Current-Asset-Value | 3.02 | |||||
| Price-to-Net-Cash | 3.58 | |||||
Earnings Yield (Greenblatt) % | -34.97 | |||||
FCF Yield % | -23.86 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ABEO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Abeona Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 25.52 | ||
| EPS (TTM) ($) | -1.17 | ||
| Beta | 1.6525 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 1.04 | ||
| Volatility % | 39.49 | ||
| 14-Day RSI | 40.62 | ||
| 14-Day ATR ($) | 0.374104 | ||
| 20-Day SMA ($) | 6.51575 | ||
| 12-1 Month Momentum % | -7.43 | ||
| 52-Week Range ($) | 4 - 7.65 | ||
| Shares Outstanding (Mil) | 57.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abeona Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Abeona Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 08:30 | In 84 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 83 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 08:30 | 7.46 (+0.81%) | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 7.46 (+0.81%) | ||
| General meeting for 2026 | 2026-06-12 09:00 | 5.53 (+3.36%) | ||
| Guidance call for 2026 | 2026-06-04 15:10 | 5.67 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 08:30 | 5.68 (-2.57%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 5.68 (-2.57%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-17 08:30 | 4.95 (+3.99%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-17 | 4.95 (+3.99%) |
Show
Entries
Abeona Therapeutics Inc Frequently Asked Questions
What is Abeona Therapeutics Inc(ABEO)'s stock price today?
The current price of ABEO is $5.98. The 52 week high of ABEO is $7.65 and 52 week low is $4.00.
When is next earnings date of Abeona Therapeutics Inc(ABEO)?
The next earnings date of Abeona Therapeutics Inc(ABEO) is 2026-11-12 Est..
Does Abeona Therapeutics Inc(ABEO) pay dividends? If so, how much?
Abeona Therapeutics Inc(ABEO) does not pay dividend.
Press Release
Articles on Abeona Therapeutics Inc
Abeona Therapeutics (ABEO) Q2 Revenue Misses Estimates; Market Pricing Reflects Growth Uncertainty
4 days ago
Headlines
See More- 1
Aug 13, 2026
Abeona outlines shift to patient-treated and net revenue reporting while targeting 85%-90% steady-state gross margins
Seeking Alpha • 11:49am
Abeona drops after Q2 revenue miss
Seeking Alpha • 9:12am
Abeona Therapeutics GAAP EPS of -$0.35 misses by $0.12, revenue of $11.38M misses by $0.78M
Seeking Alpha • 6:35am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers